~300 spots leftby Jun 2026

Veteran-Centered Care for Advanced Liver Disease (Vet-CALD Trial)

Palo Alto (17 mi)
Overseen byFasiha Kanwal, MD MSHS
Age: 18+
Sex: Any
Travel: May be covered
Time Reimbursement: Varies
Trial Phase: N/A
Recruiting
Sponsor: VA Office of Research and Development
No Placebo Group

Trial Summary

What is the purpose of this trial?Advanced liver disease is a serious illness that disproportionately affects Veterans, many of whom hope for curative liver transplantation. However, too few receive a transplant and most continue to suffer from increasing symptoms and hospitalizations. The proposed project uses a whole person, Veteran-centered approach that identifies Veterans with advanced liver disease using a population-based health management system and integrates curative and early supportive care using a telemedicine-based nurse care counselor to (1) discuss patient's understanding of illness severity and prognosis, (2) identify priorities and care preferences and (3) align curative and supportive care options to achieve patient priorities. Study outcomes include changes in (1) rates of consideration for liver transplantation, and (2) completion of serious illness discussions. Findings will inform adaptations to the intervention and facilitators for its dissemination.
What safety data exists for Veteran-Centered Care for Advanced Liver Disease?The provided research does not contain specific safety data for the treatment known as Veteran-Centered Care for Advanced Liver Disease, I-VCALD, or Vet-CALD. The articles focus on cirrhosis care strategies, mortality trends, a nurse-led clinic pilot, access to services, and advance care planning, but do not directly address safety data for the specific treatment in question.35789
Is the treatment in the trial 'Veteran-Centered Care for Advanced Liver Disease' a promising treatment?Yes, the treatment is promising because it focuses on a patient-centered approach that helps patients with advanced liver disease by integrating supportive and palliative care with other treatments. This approach allows patients, doctors, and caregivers to work together to choose the best care based on the patient's needs and priorities.23456
Do I have to stop taking my current medications for this trial?The trial protocol does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your healthcare provider.
What data supports the idea that Veteran-Centered Care for Advanced Liver Disease is an effective treatment?The available research shows that a nurse-led clinic for liver cirrhosis patients resulted in fewer unplanned hospital readmissions and improved survival rates. This suggests that integrated care models, like Veteran-Centered Care for Advanced Liver Disease, can be effective in managing advanced liver disease by reducing hospital visits and potentially increasing patient survival.14679

Eligibility Criteria

This trial is for Veterans aged 18-80 with advanced liver disease who have been in care at a recruiting site for over a year. They must speak English, have phone or computer access, and be able to consent. Those already on the transplant list or with limited life expectancy are excluded.

Inclusion Criteria

I have advanced liver disease with recent complications or a MELD-Na score over 15.
I am between 18 and 80 years old.

Exclusion Criteria

I have been diagnosed with uncontrolled mental health issues or schizophrenia.
I am currently in a hospital, long-term care facility, or nursing home.

Treatment Details

The I-VCALD study tests a telemedicine-based approach where nurses help Veterans understand their illness, identify care preferences, and align treatment options. It aims to increase rates of liver transplant consideration and serious illness discussions.
2Treatment groups
Experimental Treatment
Active Control
Group I: Arm 1: Vet-CALD InterventionExperimental Treatment1 Intervention
Vet-CALD Participants will receive the standard of care from their usual VA healthcare provider, plus they will participate in 5 monthly 60-minute care counselor sessions over a period of 6 months via VA Video Connect (VVC) or by telephone. The purpose of care counselor visits is to assess and cultivate the patient's understanding of their illness and identify personal healthcare goals. The counselor will be part of a centralized research care team (hepatologist and supportive care physician) and will work with each patient's usual VA care providers to help tailor treatment plans and education to better align with each patient's understanding of their disease prognosis and their healthcare goals and priorities.
Group II: Arm 2: Usual CareActive Control1 Intervention
Usual Care Participants will receive the standard of care from their usual VA healthcare provider. The care counselor will not contact the usual care condition participants.

Find a clinic near you

Research locations nearbySelect from list below to view details:
Central Arkansas Veterans Healthcare System , Little Rock, ARLittle Rock, AR
VA Palo Alto Health Care System, Palo Alto, CAPalo Alto, CA
VA Greater Los Angeles Healthcare System, West Los Angeles, CAWest Los Angeles, CA
Michael E. DeBakey VA Medical Center, Houston, TXHouston, TX
More Trial Locations
Loading ...

Who is running the clinical trial?

VA Office of Research and DevelopmentLead Sponsor

References

Resource utilization and survival among Medicare patients with advanced liver disease. [2021]The prevalence of advanced liver disease and its complications may be on the rise within the Medicare population. The study aim was trend assessment for prevalence, mortality and resource utilization of patients with advanced liver disease.
Comprehensive Care of Patients with Chronic Liver Disease. [2015]Chronic liver disease results from a wide range of conditions, for which individual management is beyond the scope of this article. General education, counseling, and harm reduction practices are important to the primary care of these patients, as are monitoring for cirrhosis and management of its complications. For patients with advanced liver disease, comprehensive care includes considering referral for liver transplantation, educating and empowering patients to prioritize goals of care, and optimizing symptom relief.
Advance care planning (ACP) for specialists managing cirrhosis: A focus on patient-centered care. [2018]Advance care planning (ACP) and goals of care designation (GCD) are being integrated into modern health care. In cirrhosis, uptake and adoption of these practices have been limited with physicians citing many perceived barriers and limitations. Recognizing the many tangible benefits of ACP and GCD processes in patients with life-limiting chronic diseases, the onus is on health practitioners to initiate and direct these conversations with their patients and surrogates. Drawing upon the literature and our experiences in palliative care and cirrhosis, we provide an actionable framework that can be readily implemented into a busy clinical setting by a practitioner. Conversation starters, visual aids, educational resources (for patients and practitioners), and videos of mock physician-patient scenarios are presented and discussed. Importantly, we have customized each of these tools to meet the unique health care needs of patients with cirrhosis. The inherent flexibility of our approach to ACP discussions and GCD can be further modified to accommodate practitioner preferences.
Integrated Model for Patient-Centered Advanced Liver Disease Care. [2022]Advanced liver disease (AdvLD) is a high-risk common condition with a progressive, highly morbid, and often fatal course. Despite effective treatments, there are substantial shortfalls in access to and use of evidence-based supportive and palliative care for AdvLD. Although patient-centered, chronic illness models that integrate early supportive and palliative care with curative treatments hold promise, there are several knowledge gaps that hinder development of an integrated model for AdvLD. We review these evidence gaps. We also describe a conceptual framework for a patient-centered approach that explicates key elements needed to improve integrated care. An integrated model of AdvLD would allow clinicians, patients, and caregivers to work collaboratively to identify treatments and other healthcare that best align with patients' priorities.
Access to Comprehensive Services for Advanced Liver Disease in the Veterans Health Administration. [2022]The Veterans Health Administration (VHA) provides care to the one of the largest cohorts of patients with advanced liver disease (ALD) in the USA.
Improving Advance Care Planning in Outpatients With Decompensated Cirrhosis: A Pilot Study. [2021]Despite significant morbidity and mortality among patients with decompensated cirrhosis, reported rates of advance directive (AD) completion and goals of care discussions (GCDs) between patients and providers are very low. We aimed to improve these rates by implementing a hepatologist-led advance care planning (ACP) intervention.
Core implementation strategies for improving cirrhosis care in the Veterans Health Administration. [2023]The Veterans Health Administration (VHA) provides care for more than 80,000 veterans with cirrhosis. This longitudinal, multimethod evaluation of a cirrhosis care quality improvement program aimed to (1) identify implementation strategies associated with evidence-based, guideline-concordant cirrhosis care over time, and (2) use qualitative interviews to operationalize strategies for a manualized intervention.
Mortality from chronic liver disease: Recent trends and impact of the COVID-19 pandemic. [2023]Prepandemic time trends in mortality from chronic liver disease (CLD) differed according to specific cause of death (decreasing for liver cirrhosis, stable or increasing for liver cancer), etiology (increasing for nonalcoholic fatty liver disease, generally decreasing for other etiologies), and world region (decreasing in areas with the highest burden of hepatitis B virus, increasing in Eastern Europe and other countries). The coronavirus disease 2019 (COVID-19) pandemic affected mortality of patients with CLD both directly, with a higher risk for severe illness and death depending on age, stage and etiology of the disease, and indirectly, through social isolation and loss of support, harmful drinking, and difficulties in access to care. Nevertheless, only sparse data are available on variations in CLD as a cause of death during the pandemic. In the USA, in 2020-2021 a growth in mortality was registered for all liver diseases, more marked for alcoholic liver disease, especially among young people aged 25-44 years and in selected ethnic groups. COVID-19 related deaths accounted only for a minor part of the excess. Further data from mortality registers of other countries are warranted, preferably adopting the so-called multiple cause-of-death approach, and extended to deaths attributed to viral hepatitis and liver cancer.
A novel, nurse-led 'one stop' clinic for patients with liver cirrhosis results in fewer liver-related unplanned readmissions and improved survival. [2023]Delivering effective secondary preventive and integrated care has the potential to break the revolving-door phenomenon of frequent readmissions in patients with advanced chronic liver disease. To address this, we launched the Care Coordination of Liver Disease (CCoLD) pilot, a novel nurse-led cirrhosis clinic in Western Sydney.